Results 321 to 330 of about 26,327 (353)
Some of the next articles are maybe not open access.
Renin–angiotensin system and neprilysin
2018The advent of drugs able to modulate the renin–angiotensin system (RAS), and more recently the neprilysin inhibitor sacubitril in combination with a RAS blocker, has improved the outcome of many cardiovascular and renal conditions. In particular, heart failure, post-myocardial infarction, and hypertension are the cardiovascular clinical syndromes in ...
João Pedro Ferreira, Patrick Rossignol
openaire +1 more source
Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Current Cardiology Reports, 2016Composite angiotensin receptor-neprilysin inhibition (ARNi) represents a novel pharmacologic strategy for treatment of heart failure with reduced ejection fraction (HFrEF). In the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial of 8399 subjects with HFrEF, treatment ...
Akshay S. Desai, Muthiah Vaduganathan
openaire +2 more sources
Production of soluble Neprilysin by endothelial cells
Biochemical and Biophysical Research Communications, 2014A non-membrane bound form of Neprilysin (NEP) with catalytic activity has the potential to cleave substrates throughout the circulation, thus leading to systemic effects of NEP. We used the endothelial cell line Ea.hy926 to identify the possible role of exosomes and A Disintegrin and Metalloprotease 17 (ADAM-17) in the production of non-membrane bound ...
Kuruppu, Sanjaya +3 more
openaire +4 more sources
Regulation of Thymic Development by Neprilysin Inhibition
1997Development of T lymphocyte is regulated by both thymocyte-stromal cell interactions and production of soluble factors such as cytokines, peptides and hormones. The local concentration of active biological peptides is regulated by a specialized family of enzymes expressed at the cell surface, the ectopeptidases.
Patrick Auberger, Sandrine Guérin
openaire +3 more sources
Neprilysin Inhibition for Heart Failure
New England Journal of Medicine, 2014Milton Packer +2 more
openaire +6 more sources
State of the art on angiotensin-neprilysin inhibitors
Minerva Cardiology and AngiologyAngiotensin receptor neprilysin inhibitor (ARNI) decreases renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous systems (SNS) activity promoting vasodilation, decreasing myocardial hypertrophy and fibrosis. Beyond the SNS, RAAS and natriuretic peptide systems, ARNI results in increased circulatory and myocardial nitric oxide levels ...
Anusha, Sunkara +3 more
openaire +2 more sources
Convoluted molecular maze of neprilysin
Diagnosis, 2022Eleftherios P. Diamandis +2 more
openaire +2 more sources